Independent Findings Show Successful Non-Invasive Treatment Of Plantar Fasciitis & Osteoarthritis By Surgeons Utilizing PX50™ Amniotic Allograft

Surgeons at separate in-office clinics independently have found that just one application of PX50™ shows successful results in non-invasive treatments for patients with plantar fasciitis and osteoarthritis, after failed conservative management.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
“Skye is very excited at the success and adoption of our surgical offering (CryoMatrix™ & ActiveBarrier™), and office line (PX50™) of amniotic & placenta biologic products.

Redondo Beach, CA (PRWEB) June 12, 2014

Skye OrthoBiologics, LLC is a regenerative and osteobiologic solutions Biotechnology Company engaged in the development and commercialization of novel human tissue-based amniotic and placental biologic products. Skye is dedicated to creating, engineering and advancing industry-leading biologics under its BioECM® product line.

Surgeons at separate in-office clinics independently have found that just one application of PX50™ shows successful results in non-invasive treatments for patients with plantar fasciitis and osteoarthritis, after failed conservative management.

PX50™ is exclusively formulated for and offered by Skye and is part of its cutting edge & diverse line of Next Generation Active BioECM® Orthopedic (ECM is a dynamic protein system that provides the foundation for all of the body’s organs and tissues) biologic products derived from amniotic and placental tissues.

“Skye is very excited at the success and adoption of our surgical offering (CryoMatrix™ & ActiveBarrier™), and office line (PX50™) of amniotic & placenta biologic products. Our BioECM® biologics are demonstrating to be an ideal solution for the treatment of many injuries and surgical challenges,” commented CEO, Chris Sharp. “We have developed one of the industries most diverse active ECM biologic lines through our proprietary processing techniques and are thrilled to be sharing them with the medical community.”

For additional information on these independently observed plantar fasciitis and osteoarthritis results, please contact Skye Orthobiologics.

Skye is actively looking to expand its national and international distribution network for its exclusive amniotic tissue biologics.

About SKYE:
Skye Orthobiologics, LLC is a leading osteobiologics and regenerative biologics company engaged in the research, development and commercialization of novel biologic products derived from natural biologics and placental tissues. Our research, development and advancement efforts are focused on the extracellular nature and regenerative potential of placental tissues given their complex protein biologic structure that has demonstrated excellent clinical effectiveness over the last 10 years.

Skye continues to advance The Power of the Body. The Innovation of Science.® by focusing on the regenerative potential of the human body. For more information, visit our website at http://www.skyebiologics.com.

Marketing / Sales Enquiries:
Chris Sharp
CEO
310.944.5402
csharp(at)skyebiologics(dot)com

Forward-looking statement
Any forward-looking statement is based on information available to Skye Orthobiologics, LLC as of the date of the statement. All written or oral forward-looking statements attributable to Skye Orthobiologics LLC are qualified by this caution. Skye does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Skye’s expectations.


Contact